Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the ...

October 9, 2008 — Stool DNA testing is a new approach to screening for colorectal cancer, but it is an evolving technology. A study has found that the first-generation stool DNA test (SDT-1) is not ...

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for ...

Stool-based tests for colorectal cancer (CRC) screening show no significant difference in detecting advanced neoplasia overall, but for advanced serrated lesions specifically, the multitarget stool ...

INDIANAPOLIS -- A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas ...

CT colonography reduced the incidence of colorectal cancer by up to 75% versus no screening, while stool DNA testing reduced the incidence by 59%. Stool testing was cost-effective relative to no ...

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Trends in utilization of colorectal cancer screening modalities among patients with average risk in the United States from 2017 to 2023. This is an ASCO Meeting Abstract from the 2025 ASCO ...

WASHINGTON (AP) — In a story March 24 about colon cancer screening tests, The Associated Press reported erroneously that the Colosure test from LabCorp is approved by the Food and Drug Administration.